

# OPAL BIOSCIENCES INVESTOR BRIEFING

MONDAY 13 JULY 2015

Antibiotic resistant superbugs are becoming one of the biggest health issues of the 21st century. A UK government report estimates that by 2050, an average of 10 million people will die every year and cost the global economy up to \$100 trillion if we fail to fight these diseases.



Opal Biosciences is an innovative Australian company player working on infectious disease treatments and tackling this serious global health threat.

The Company's technology has demonstrated activity against a wide range of human disease-causing germs and has the potential to combat dangerous superbugs.

Opal offers a unique opportunity for sophisticated investors to invest in the development of anti-infective treatments.

Join Opal Biosciences' Managing Director Julie Phillips to discuss the Company's position in this highly promising field and the Company's investment potential.

The presentation will be followed by a Q and A session and light refreshments.

**DATE:** MONDAY JULY 13, 2015  
**TIME:** 1PM-2PM  
**LOCATION:** SHAW STOCKBROKING  
LEVEL 15, 60 CASTLEREAGH STREET, SYDNEY  
**RSVP:** GABRIELLA HOLD, BUCHAN CONSULTING  
ghold@buchanwe.com.au or call 03 8866 1203 by Thursday, July 9, 2015

